We were delighted to catch up with our Editorial Board member, Prof. Toby Maher (University of Southern California, Los Angeles, CA, USA) during the ERS Virtual Congress, to discuss the ISABELA study in IPF (NCT03711162) and the challenges the trial has faced during the COVID-19 pandemic.
Questions
- What are the major unmet needs in the treatment of idiopathic pulmonary fibrosis (IPF)? (0:11)
- Could you tell us a little about ziritaxestat and its mechanism of action? (1:30)
- Could you give us an overview of the ISABELA clinical trial program and its findings to date? (2:28)
- What are the next steps in the clinical development of ziritaxestat? (3:46)
- What are the major challenges of conducting IPF clinical trials in the era of COVID-19? (5:07)
Speaker disclosure: Toby Maher has acted as a consultant and speaker for Boehringer Ingelheim, Galapagos and Roche.
Support: Interview and filming supported by Touch Medical Media.
Filmed in coverage of the ERS International Congress 2020.
